Screening for Prostate Cancer - More Questions than Answers

References

• Schröder FH, Boyle P. Screening for prostate cancer-ne-cessity or nonsense? Eur J Cancer 1993; 29A: 656–61.
   PubMed Web of Science ®Google Scholar
• Chodak GW. Questioning the value of screening for prostate cancer in asymptomatic men (editorial). Urology 1993; 42: 116–8.
   PubMedGoogle Scholar
• Collins MM, Barry MJ. Controversies in prostate cancer screening. Analogies to the early lung cancer screening de-bate. JAMA 1996; 276: 1976–9.
   Google Scholar
• American Urological Association: Position statement. An-nual meeting, May 1993.
   Google Scholar
• American Cancer Society. Position statement. Annual meet-ing, May 1993.
   Google Scholar
• Adami HO, Baron JA, Rothman KJ. Ethics of a prostate cancer screening trial. Lancet 1994; 343: 958–60.
   PubMed Web of Science ®Google Scholar
• Visser O, Coebergh JWW, Schouten U. Incidence of cancer in the Netherlands: The fourth report of the Netherlands cancer registry. Utrecht: SIG Health Care Information, 1995.
   Google Scholar
• Lu-Yao GL, Greenberg ER. Changes in prostate cancer incidence and treatment in the USA. Lancet 1994; 343: 251–4.
   Google Scholar
• Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995; 273: 548–52.
   PubMed Web of Science ®Google Scholar
• Moller Jensen O, Esteve J, Moller H, Renard H. Cancer in the European Community and its member states. Eur J Cancer 1990; 26: 1167–256.
   PubMedGoogle Scholar
• Boyle P, Maisonneuve P, Napalkov P. Geographical and temporal patterns of incidence and mortality from prostate cancer. Urology 1995; 46 (Suppl 3A): 47–55.
   Google Scholar
• Seidman H, Mushinski MH, Gelb SK, Silverberg E. Proba-bilities of eventually developing or dying of cancer-United States, 1985. CA Cancer J Clin 1985; 35: 36–56.
   PubMed Web of Science ®Google Scholar
• Wilson JMG, Jungner G. Principles and practice of screen-ing for disease. Geneva: WHO, 1968: Public Health Paper No. 34.
   Google Scholar
• Franks LM. Latent carcinoma of the prostate. J Pathol Bacteriol 1954; 68: 603–16.
   PubMedGoogle Scholar
• Gaynor EP. Zur frage des prostatakrebs. Virchow's Arch Path Anat 1938; 301: 602–52.
   Google Scholar
• Holund B. Latent prostate cancer in a consecutive autopsy series. Scand J Urol Nephrol 1980; 14: 29–35.
   PubMed Web of Science ®Google Scholar
• Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993; 150: 379–85.
   Google Scholar
• Montie JE, Wood DP, Pontes JE, Boyett JM, Levin HS. Adenocarcinoma of the prostate in cystoprostatectomy spec-imens removed for bladder cancer. Cancer 1989; 63: 381–5.
   Google Scholar
• Kabalin JN, McNeal JE, Price HM, Freiha FS, Stamey TA@. Unsuspected adenocarcinoma of the prostate in pa-tients undergoing cystoprostatectomy for other causes: inci-dence, histology and morphometric observations. J Urol 1989;141: 1091–4; discussion 1093–4.
   Google Scholar
• Ohori M, Wheeler TM, Dunn JK, Stamey TA, Scardino PT. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol 1994; 152: 1714–20.
   Google Scholar
• Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whitte-more AS, Schmid HP. Localized prostate cancer. Relation-ship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993; 71 (Suppl 3): 933–8.
   Google Scholar
• Surveillance, Epidemiology and end results. Incidence and mortality data: 1973–1977. Bethesda (MD): National Can-cer Institute Monograph 57; 1981; publication No (NIH) 81–2330.
   Google Scholar
• Murphy GP, Natarajan N, Pontes JE, et al. The national survey of prostate cancer in the United States by the Amer-ican College of Surgeons. J Urol 1982; 127: 928–34.
   PubMed Web of Science ®Google Scholar
• Visser O, Horenblas S. Incidentie en behandeling van prostaatcarcinoom in de regio van het integraal kankercen-trum Amsterdam, 1989–1994. Ned Tijdschr Geneeskd 1996; 140: 2627–31.
   Google Scholar
• Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419–24.
   PubMed Web of Science ®Google Scholar
• Bumpus HC. Carcinoma of the prostate. A clinical study of one thousand cases. Surg Gynecol Obstet 1926; 46: 150–5.
   Google Scholar
• Nesbit RM, Plumb RT. Prostatic carcinoma. A follow-up on 795 patients treated prior to the endocrine era and a com-parison of survival-rates between these and patients treated by endocrine therapy. Surgery 1946; 20: 263–72.
   Google Scholar
• Handley R, Carr TW, Travis D, Powell PH, Hall RR. Deferred treatment for prostate cancer. Br J Urol 1988; 62: 249–53.
   Google Scholar
• Johansson JE, Adami HO, Andersson SO, Bergstrom R, Holmberg L, Krusemo UB. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA 1992; 267: 2191–6.
   PubMed Web of Science ®Google Scholar
• Johansson JE. Expectant management of early stage pro-static cancer: Swedish experience. J Urol 1994; 152: 1753–6.
   PubMedGoogle Scholar
• Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO. Fifteen-year survival in prostate cancer. Aprospective, population-based study in Sweden. JAMA 1997; 277: 467–71.
   Google Scholar
• Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate can-cer. N Engl J Med 1994; 330: 242–8.
   PubMed Web of Science ®Google Scholar
• Aus G, Pileblad E, Hugosson J. Impact of competing mor-tality on the cancer-related mortality in localized prostate cancer. Urology 1995; 46: 672–5.
   Google Scholar
• Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995; 274: 626–31.
   Google Scholar
• Schmid HP, McNeal JE, Stamey TA. Clinical observations on the doubling time of prostate cancer. Eur Urol 1993; 23 (Suppl 2): 60–3.
   Google Scholar
• Schmid HP, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a mea-sure of increasing cancer volume. Cancer 1993; 71: 2031–40.
   Google Scholar
• Ohori M, Scardino PT. Early detection of prostate cancer: the nature of cancers detected with current diagnostic tests. Semin Oncol 1994; 21: 522–6.
   PubMedGoogle Scholar
• Scardino PT, Weaver R, Hudson MA. Early detection of prostate cancer. Hum Pathol 1992; 23: 211–22.
   Google Scholar
• McNeal JE, Bostwick DG, Kindrachuk RA, Redwine EA, Freiha FS, Stamey TA. Patterns of progression in prostate cancer. Lancet 1986; 1: 60–3.
   PubMed Web of Science ®Google Scholar
• McNeal JE, Villers AA, Redwine EA, Freiha FS, Stamey TA. Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer 1990; 66: 1225–33.
   Google Scholar
• Breslow N, Chan CW, Dhom G, et al. Latent carcinoma of the prostate at autopsy in seven areas. Int J Cancer 1977; 20: 680–8.
   PubMed Web of Science ®Google Scholar
• Haenszel W, Kurihara M. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 1968; 40: 43–68.
   PubMed Web of Science ®Google Scholar
• Mills PK, Beeson WL, Phillips RL, Fraser GE. Cohort study of diet, lifestyle, and prostate cancer in Adventist men. Cancer 1989; 64 (3): 598–604.
   PubMed Web of Science ®Google Scholar
• Clinton SK, Emenhiser C, Schwartz SJ, et al. Cis-trans lycopene isomers, carotenoids, and retinol in the human prostate. Cancer Epidemiol Biomarkers Prey 1996; 5: 823–33.
   PubMed Web of Science ®Google Scholar
• Giovannucci E, Ascherio A, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst 1995; 87: 1767–76.
   PubMed Web of Science ®Google Scholar
• Rao GN. Influence of diet on tumors of hormonal tissues. Prog Clin Biol Res 1996; 394: 41–56.
   PubMedGoogle Scholar
• Gann PH, Hennekens CH, Sacks FM, et al. Prospective study of plasma fatty acids and risk of prostate cancer. Journal of the National Cancer Institute 1994; 86: 281–6.
   PubMedGoogle Scholar
• Wang Y, Corr JG, Thaler HT, Tao Y, Fair WR, Heston WD. Decreased growth of established human prostate LN-CaP tumors in nude mice fed a low-fat diet. J Natl Cancer Inst 1995; 87: 1456–62.
   PubMed Web of Science ®Google Scholar
• Bastacky SI, Wojno KJ, Walsh PC, Carmichael MJ, Epstein K. Pathological features of hereditary prostate cancer. J Urol 1995; 153: 987–92.
   Google Scholar
• Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate cancer. Prostate 1990; 17: 337–47.
   Google Scholar
• Tsukamoto S, Akaza H, Onozawa M, Imade S, Tsukuba, Shirai T. Chemoprevention of rat prostate carcinogenesis by use of finasteride or casodex: A study of dose finding (Ab-stract 886). J Urol 1997; 157: 227.
   Google Scholar
• Pienta KJ, Esper PS, Zwas F, Krzeminski R, Flaherty LE. Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the prostate. Am J Clin Oncol 1997; 20: 36–9.
   PubMed Web of Science ®Google Scholar
• Brawley OW, Ford LG, Thompson I, Perlman JA, Kramer BS. 5-Alpha-reductase inhibition and prostate cancer pre-vention. Cancer Epidemiol Biomarkers Prey 1994; 3: 177–82.
   PubMed Web of Science ®Google Scholar
• Brawley OW, Thompson IM. Chemoprevention of prostate cancer. Urology 1994; 43: 594–9.
   PubMed Web of Science ®Google Scholar
• Mettlin C, Natarajan N, Murphy GP. Recent patterns of care of prostate cancer patients in the United States: results from the surveys of the American College of Surgeons Commission on Cancer. Int Adv Surg Oncol 1982; 5: 277–321.
   Google Scholar
• Rosen MA, Goldstone L, Lapin S, Wheeler T, Scardino PT. Frequency and location of extracapsular extension and posi-tive surgical margins in radical prostatectomy specimens. J Urol 1992; 148: 331–7.
   Google Scholar
• Stamey TA, Ferrari MK, Schmid HP. The value of serial prostate specific antigen determinations 5 years after radio-therapy: steeply increasing values characterize 80% of pa-tients. J Urol 1993; 150: 1856–9.
   Google Scholar
• Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156–61.
   PubMed Web of Science ®Google Scholar
• Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993; 270: 948–54.
   PubMed Web of Science ®Google Scholar
• Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific anti-gen in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J Urol 1994; 151: 1283–90.
   PubMed Web of Science ®Google Scholar
• Mettlin C, Murphy GP, Lee F, et al. Characteristics of prostate cancer detected in the American Cancer Society-Na-tional Prostate Cancer Detection Project. J Urol 1994; 152: 1737–40.
   PubMedGoogle Scholar
• Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995; 273: 289–94.
   Google Scholar
• Watanabe H, Kaiho H, Tanaka M, Terasawa Y. Diagnostic application of ultrasonotomography to the prostate. Invest Urol 1971; 8: 548–59.
   PubMedGoogle Scholar
• Watanabe H, Igari D, Tanahashi Y, Harada K, Saitoh M. Transrectal ultrasonotomography of the prostate. J Urol 1975; 114: 734–9.
   Google Scholar
• Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purifica-tion of a human prostate specific antigen. Invest Urol 1979; 17: 159–63.
   PubMedGoogle Scholar
• Lilja H, Laurell CB. Liquefaction of coagulated human semen. Scand J Clin Invest 1984; 44: 447–52.
   PubMed Web of Science ®Google Scholar
• Lepor H, Wang B, Shapiro E. Relationship between pro-static epithelial volume and serum prostate-specific antigen levels. Urology 1994; 44: 199–205.
   Google Scholar
• Elgamal AA, Ectors NL, Sunardhi-Widyaputra S, Van Pop-pel HP, Van Damme BJ, Baert LV. Detection of prostate specific antigen in pancreas and salivary glands: a potential impact on prostate cancer overestimation. J Urol 1996; 156: 464–8.
   Google Scholar
• Graves HCB. Nonprostatic sources of prostate-specific anti-gen: a steroid hormone dependent phenomenon? Clin Chem 1995; 41: 7–9.
   PubMedGoogle Scholar
• Agha AH, Schechter E, Roy JB, Culkin DJ. Prostate specific antigen is metabolized in the liver. J Urol 1996; 155: 1332–5.
   PubMedGoogle Scholar
• Aus G, Bergdahl S, Frosing R, Lodding P, Pileblad E, Hugosson J. Reference range of prostate-specific antigen after trans-urethral resection of the prostate. Urology 1996; 47 (4): 529–31.
   PubMedGoogle Scholar
• Yuan JJJ, Coplen DE, Petros JA, et al. Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate specific antigen levels. J Urol 1992; 147: 810–4.
   PubMed Web of Science ®Google Scholar
• Breul J, Binder K, Block T, Hartung R. Effect of digital rectal examination on serum concentration of prostate-spe-cific antigen. Eur Urol 1992; 21: 195–9.
   PubMedGoogle Scholar
• Tchetgen MB, Song JT, Strawderman M, Jacobsen SJ, Oesterling JE. Ejaculation increases the serum prostate-spe-cific antigen concentration. Urology 1996; 47: 511–6.
   Google Scholar
• Herschman JD, Smith DS, Catalona WJ. Effect of ejacula-tion on serum total and free prostate-specific antigen concen-trations. Urology 1997; 50: 239–43.
   Google Scholar
• Kirkali Z, Kirkali G, Esen A. Effect of ejaculation on prostate-specific antigen levels in normal men. Eur Urol 1995; 27: 292–4.
   Google Scholar
• Netto NR Jr, Apuzzo F, de Andrade E, Srulzon GB, Cor-tado PL, Lima ML. The effects of ejaculation on serum prostate specific antigen. J Urol 1996; 155: 1329–31.
   Google Scholar
• Simak R, Madersbacher S, Zhang ZF, Maier U. The impact of ejaculation on serum prostate specific antigen. J Urol 1993; 150: 895–7.
   PubMed Web of Science ®Google Scholar
• Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909–16.
   PubMed Web of Science ®Google Scholar
• Stamey TA, Kabalin JN, McNeal JE, et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 1989; 141: 1076–83.
   Google Scholar
• Parkes C, Wald NJ, Murphy P, et al. Prospective observa-tional study to assess value of prostate specific antigen as screening test for prostate cancer. Br Med J 1995; 311: 1340–3.
   PubMedGoogle Scholar
• Whittemore AS, Lele C, Friedman GD, Stamey T, Vogel-man JH, Orentreich N. Prostate-specific antigen as predictor of prostate cancer in black men and white men. J Natl Cancer Inst 1995; 87: 354–60.
   Google Scholar
• Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J. Serum concentrations of prostate specific anti-gen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet 1994; 344: 1594–8.
   PubMed Web of Science ®Google Scholar
• Catalona WJ, Hudson MA, Scardino PT, et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol 1994; 152: 2037–42.
   PubMed Web of Science ®Google Scholar
• Labrie F, Dupont A, Suburu R, et al. Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol 1992; 147: 846–51.
   PubMed Web of Science ®Google Scholar
• Babaian RJ, Mettlin C, Kane R, et al. The relationship of prostate-specific antigen to digital rectal examination and transrectal ultrasonography. Findings of the American Can-cer Society National Prostate Cancer Detection Project. Cancer 1992; 69: 1195–200.
   Google Scholar
• Mettlin C, Lee F, Drago J, Murphy GP. The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men. Cancer 1991; 67: 2949–58.
   Google Scholar
• Mettlin C, Murphy GP, Babaian RJ, et al. The results of a five-year early prostate cancer detection intervention. Inves-tigators of the American Cancer Society National Prostate Cancer Detection Project. Cancer 1996; 77: 150–9.
   Google Scholar
• Gustafsson O, Norming U, Almgard LE, et al. Diagnostic methods in the detection of prostate cancer: a study of a randomly selected population of 2400 men. J Urol 1992; 148: 1827–31.
   Google Scholar
• Crawford ED, DeAntoni EP, Etzioni R, Schaefer VC, Olson RM, Ross CA. Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. The Prostate Cancer Education Council. Urology 1996; 47: 863–9.
   Google Scholar
• Cooner WH, Mosley BR, Rutherford CL, Jr, et al. Prostate cancer detection in a clinical urological practice by ultra-sonography, digital rectal examination and prostate specific antigen. J Urol 1990;143: 1146–2; discussion 1152–4.
   Google Scholar
• Chodak GW, Keller P, Schoenberg HW. Assessment of screening for prostate cancer using the digital rectal exami-nation. J Urol 1989; 141: 1136–8.
   Google Scholar
• Pedersen KV, Carlsson P, Varenhorst E, Lofman O, Berglund K. Screening for carcinoma of the prostate by digital rectal examination in a randomly selected population. Br Med J 1991; 300: 1041–4.
   Google Scholar
• Smith DS, Catalona WJ. Interexaminer variability of digital rectal examination in detecting prostate cancer. Urology 1995; 45: 70–4.
   PubMed Web of Science ®Google Scholar
• Lee F, Gray JM, McLeary RD, et al. Transrectal ultrasound in the diagnosis of prostate cancer: location, echogenicity, histopathology, and staging. Prostate 1985; 7: 117–29.
   PubMed Web of Science ®Google Scholar
• Terris MK, Freiha FS, McNeal JE, Stamey TA. Efficacy of transrectal ultrasound for identification of clinically unde-tected prostate cancer. J Urol 1991; 146: 78–83; discussion 83-84.
   PubMed Web of Science ®Google Scholar
• Lee F, Torp-Pedersen S, Littrup PJ, et al. Hypoechoic lesions of the prostate: clinical relevance of tumor size, digital rectal examination and prostate specific antigen. Ra-diology 1989; 170: 29–32.
   Google Scholar
• Ellis WJ, Chetner MP, Preston SD, Brawer MK. Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasono-graphy. J Urol 1994; 152: 1520–5.
   PubMed Web of Science ®Google Scholar
• Schröder FH, Hermanek P, Denis L, Fair WR, Gospo-darowicz MK, Pavone-Macaluso M. The TNM classification of prostate cancer. Prostate 1992; 4: 129–38.
   Google Scholar
• Epstein JI, Walsh PC, Carmichael M, Brendler CB. Patho-logic and clinical findings to predict tumor extent of nonpal-pable (stage Tic) prostate cancer. JAMA 1994; 271: 368–74.
   PubMed Web of Science ®Google Scholar
• Brendler CB. Characteristics of prostate cancer found with early detection regimens. Urology 1995; 46 (Suppl 3A): 71–6.
   Google Scholar
• Matthews GJ, Fracchia JA. PSA-detected prostate cancer: contrasts with palpable disease. J Surg Oncol 1995; 59: 28–30.
   PubMedGoogle Scholar
• Oesterling JE, Suman VJ, Zincke H, Bostwick DG. PSA-de-tected (clinical stage Tic or BO) prostate cancer. Pathologi-cally significant tumors. Urol Clin North Am 1993; 20: 687–93.
   PubMedGoogle Scholar
• Babaian RJ, Fritsche HA, Evans RB. Prostate-specific anti-gen and prostate gland volume: correlation and clinical application. J Clin Lab Anal 1990; 4: 135–7.
   Google Scholar
• Babaian RJ, Miyashita H, Evans RB, Ramirez EL The distribution of prostate specific antigen in men without clinical or pathological evidence of prostate cancer: relation-ship to gland volume and age. J Urol 1992; 147: 837–40.
   PubMed Web of Science ®Google Scholar
• Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992; 147: 817–21.
   Google Scholar
• Benson MC, Whang IS, Pantuck A, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992; 147: 815–6.
   PubMed Web of Science ®Google Scholar
• Bazinet M, Meshref AW, Trudel C, et al. Prospective evalu-ation of prostate specific antigen density and systematic biopsies for early detection of prostatic carcinoma. Urology 1994; 43: 44–52.
   PubMed Web of Science ®Google Scholar
• Littrup PJ, Kane RA, Mettlin CJ, et al. Cost-effective prostate cancer detection. Reduction of low-yield biopsies. Investigators of the American Cancer Society National Prostate Cancer Detection Project. Cancer 1994; 74: 3146–58.
   Google Scholar
• Catalona WJ, Richie JP, deKernion JB, et al. Comparison of prostate specific antigen concentration versus prostate spe-cific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J Urol 1994; 152: 2031–6.
   PubMed Web of Science ®Google Scholar
• Cookson MS, Floyd MK, Ball TP, Jr, Miller EK, Sarosdy MF. The lack of predictive value of prostate specific antigen density in the detection of prostate cancer in patients with normal rectal examinations and intermediate prostate spe-cific antigen levels. J Urol 1995; 154: 1070–3.
   PubMed Web of Science ®Google Scholar
• Bare R, Hart L, McCullough DL. Correlation of prostate-specific antigen and prostate-specific antigen density with outcome of prostate biopsy. Urology 1994; 43: 191–6.
   Google Scholar
• Ohori M, Dunn JK, Scardino PT. Is prostate-specific antigen density more useful than prostate-specific antigen levels in the diagnosis of prostate cancer? Urology 1995; 46: 666–71.
   Google Scholar
• Brawer MK, Aramburu EA, Chen GL, Preston SD, Ellis WJ. The inability of prostate specific antigen index to en-hance the predictive value of prostate specific antigen in the diagnosis of prostatic carcinoma. J Urol 1993; 150: 369–73.
   Google Scholar
• Bosch JL, Hop WC, Bangma CH, Kirkels WJ, Schröder FH. Prostate specific antigen in a community-based sample of men without prostate cancer: correlations with prostate vol-ume, age, body mass index, and symptoms of prostatism. Prostate 1995; 27: 241–9.
   Google Scholar
• Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993; 270: 860–4.
   Google Scholar
• Oesterling JE, Jacobsen SJ, Cooner WH. The use of age-spe-cific reference ranges for serum prostate specific antigen in men 60 years old or older. J Urol 1995; 153: 1160–3.
   Google Scholar
• Partin AW, Criley SR, Subong EN, Zincke H, Walsh PC, Oesterling JE. Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis. J Urol 1996; 155: 1336–9.
   PubMedGoogle Scholar
• el-Galley RES, Petros FRCS, Sanders WH, et al. Normal range prostate specific antigen versus age specific prostate specific antigen in screening prostate adenocarcinoma. Urol-ogy 1995; 46: 200–4.
   Google Scholar
• Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan 0. A complex between prostate spe-cific antigen and al-antichimotrypsin is the major form of prostate specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: 222–6.
   Google Scholar
• Catalona WJ, Smith DS, Wolfert RL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995; 274: 1214–20.
   PubMed Web of Science ®Google Scholar
• Van Cangh PJ, De Nayer P, Sauvage P, et al. Free to total prostate-specific antigen (PSA) ratio is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancer. Prostate 1996; 7: 30–4.
   Google Scholar
• Bangma CH, Rietbergen JB, Kranse R, Blijenberg BG, Petterson K, Schröder FH. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general popu-lation. J Urol 1997; 157: 2191–6.
   Google Scholar
• Hugosson J, Aus G, Bergdahl S, et al. Results of a popula-tion bases randomized study of PSA screening for prostate cancer (Abstract 459). J Urol 1997; 157: 118.
   Google Scholar
• Bangma CH, Rietbergen JBW, Schröder FH. Prostate spe-cific antigen as a screening test: The Netherlands experience. Urol Clin North Am 1997; 24: 307–14.
   Google Scholar
• Roehrborn CG, Gregory A, McConnell JD, Sagalowsky Al, Wians FH, Jr. Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-spe-cific antigen in predicting prostate histology. Urology 1996; 48 (Suppl 6A): 23–32.
   Google Scholar
• Eposti PL, Elman A, Norlen H. Complications of transrectal aspiration biopsy of the prostate. Scand J Urol Nephrol 1975; 9: 208–13.
   PubMedGoogle Scholar
• Edson RS, Scoy van RE, Leary FJ. Gram negative bac-teremia after transrectal needle biopsy of the prostate. Mayo Clin Proc 1980; 55: 489–91.
   PubMedGoogle Scholar
• Davison P, Malament M. Urinary contamination as a result of transrectal biopsy of the prostate. J Urol 1971; 105: 545–6.
   PubMed Web of Science ®Google Scholar
• Norberg M. Transrectal ultrasound and core biopsies for the diagnosis of prostate cancer. Acta Radiol 1994; 393: 1–21.
   Google Scholar
• Terris MK, McNeal JE, Stamey TA. Detection of clinically significant prostate cancer by transrectal ultrasound-guided systematic biopsies. J Urol 1992; 148: 829–32.
   Google Scholar
• Daneshgari F, Taylor GD, Miller GJ, Crawford ED. Com-puter simulation of the probability of detecting low volume carcinoma of the prostate with six random systematic core biopsies. Urology 1995; 45: 604–9.
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Pickens GJ, Sanders JS. Diagnostic yield of repeated transrectal ultrasound-guided biopsies stratified by specific histopathologic diagnoses and prostate specific anti-gen levels. Urology 1996; 47: 347–52.
   Google Scholar
• Karakiewicz PI, Bazinet M, Aprikian AG, et al. Outcome of sextant biopsy according to gland volume. Urology 1997; 49: 55–9.
   PubMed Web of Science ®Google Scholar
• Uzzo RG, Wei JT, Waldbaum RS, Perlmutter AP, Byrne JC, Vaughan ED. The influence of prostate size on cancer detection. Urology 1995; 46: 831–6.
   PubMedGoogle Scholar
• Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997; 157: 199–202; discussion 202-3.
   Google Scholar
• Goldstein NS, Begin LR, Grody WW, Novak JM, Qian J, Bostwick DG. Minimal or no cancer in radical prostatec-tomy specimens. Report of 13 cases of the 'vanishing cancer phenomenon'. Am J Surg Pathol 1995; 19: 1002–9.
   Google Scholar
• Ravery V, Szabo J, Toublanc M, et al. A single positive prostate biopsy in six does not predict a low-volume prostate tumour. Br J Urol 1996; 77: 724–8.
   PubMedGoogle Scholar
• Cupp MR, Bostwick DG, Myers RP, Oesterling JE. The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostate-ctomy specimen on an individual basis. J Urol 1995; 153: 1543–8.
   PubMed Web of Science ®Google Scholar
• Epstein JI, Walsh PC, Brendler CB. Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experi-ence with tumors found on transurethral resection (stages T IA and TIB) and on needle biopsy (stage TIC). J Urol 1994; 152: 1721–9.
   Google Scholar
• Bostwick DG. Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched prostatectomies. Amer J Surg Path 1994; 18: 796–803.
   Google Scholar
• Johnstone PA, Riffenburgh R, Saunders EL, Willison FW. Grading inaccuracies in diagnostic biopsies revealing pro-static adenocarcinoma: implications for definitive radiation therapy. Int J Radiat Oncol Biol Phys 1995; 32: 479–82.
   PubMedGoogle Scholar
• Epstein JI, Steinberg GD. The significance of low-grade prostate cancer on needle biopsy. A radical prostatectomy study of tumor grade, volume, and stage of the biopsied and multifocal tumor. Cancer 1990; 66: 1927–32.
   Google Scholar
• Kojima M, Troncoso P, Babaian RJ. Use of prostate-specific antigen and tumor volume in predicting needle biopsy grad-ing error. Urology 1995; 45: 807–12.
   Google Scholar
• Bostwick DG, Qian J, Bergstralh E, et al. Prediction of capsular perforation and seminal vesicle invasion in prostate cancer. J Urol 1996; 155: 1361–7.
   PubMed Web of Science ®Google Scholar
• Amico AV, Chang H, Holupka E, et al. Calculated prostate cancer volume: the optimal predictor of actual cancer vol-ume and pathologic stage. Urology 1997; 49: 385–91.
   PubMedGoogle Scholar
• Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150: 110–4.
   PubMed Web of Science ®Google Scholar
• Partin AW, Kattan MW, Subong ENP, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. JAMA 1997; 277: 1445–51.
   PubMed Web of Science ®Google Scholar
• Labrie F, Dupont A, Suburu R, et al. Optimized strategy for detection of early stage, curable prostate cancer: role of prescreening with prostate-specific antigen. Clin Invest Med 1993; 16: 425–39.
   PubMed Web of Science ®Google Scholar
• Smith DS, Catalona WJ, Herschman JD. Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA 1996; 276: 1309–15.
   Google Scholar
• Carter HB, Epstein JI, Chan DW, Fozard JL, Pearson JD. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA 1997; 277: 1456–60.
   Google Scholar
• Graversen PH, Nielsen KT, Gasser TC, DKC, Madsen PO. Radical prostatectomy versus expectant primary treatment in stages I and II prostatic cancer. Urology 1990; 36: 493–498.
   Google Scholar
• Paulson DF, Lin GH, Hinshaw W, Stephani S. Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J Urol 1982; 128: 502–4.
   PubMed Web of Science ®Google Scholar
• Wilt TJ, Brawer MK. The Prostate Cancer Intervention Versus Observation Trial: a randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer. J Urol 1994; 152 (5 Pt 2): 1910–4.
   Google Scholar
• Norlen BJ. Swedish randomized trial of radical prostatec-tomy versus watchful waiting. Can J Oncol 1994; 4: 38–40.
   PubMedGoogle Scholar
• Austenfeld MS, Thompson IM, Jr, Middleton RG. Meta-analysis of the literature: guideline development for prostate cancer treatment. American Urological Association Prostate Cancer Guideline Panel. J Urol 1994; 152: 1866–9.
   Google Scholar
• Middleton RG, Thompson IM, Austenfeld MS, et al. Prostate Cancer Clinical Guidelines Panel summary report on the management of clinically localized prostate cancer. The American Urological Association. J Urol 1995; 154: 2144–8.
   Google Scholar
• Hanks GE, Asbell S, Kra11 JM, et al. Outcome for lymph node dissection negative T-lb, T-2 (A-2,B) prostate cancer treated with external beam radiation therapy in RTOG 77-06. Int .1- Radiat Oncol Biol Phys 1991; 21: 1099–103.
   Google Scholar
• Powell CR, Huisman TK, Riffenburgh RH, Saunders EL, Bethel KJ, Johnstone PAS. Outcome for surgically staged localized prostate cancer treated with external beam radia-tion therapy. J Urol 1997; 157: 1754–9.
   PubMedGoogle Scholar
• Gerber GS, Thisted RA, Scardino PT, et al. Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA 1996; 276: 615–9.
   PubMedGoogle Scholar
• Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 1997; 349: 906–10.
   Google Scholar
• Partin AW, Lee BR, Carmichael M, Walsh PC, Epstein JI. Radical prostatectomy for high grade disease: a re-evalua-tion 1994. J Urol 1994; 151: 1583–6.
   Google Scholar
• Ohori M, Goad JR, Wheeler TM, Eastham JA, Thompson TC, Scardino PT. Can radical prostatectomy alter the pro-gression of poorly differentiated prostate cancer? J Urol 1994; 152: 1843–9.
   PubMed Web of Science ®Google Scholar
• Chodak GW, Thisted RA. Comparison of cancer specific survival (CSS) following radical prostatectomy (RP) or watchful waiting (WW) based on two multi-institutional pooled analyses (Abstract 995). J Urol 1996; 155 (Suppl 5): 559A.
   Google Scholar
• Litwin MS, Hays RD, Fink A, et al. Quality-of-life out-comes in men treated for localized prostate cancer. JAMA 1995; 273: 129–35.
   PubMed Web of Science ®Google Scholar
• Wasson JH, Cushman CC, Bruskewitz RC, Littenberg B, Mulley AG, Jr, Wennberg JE. A structured literature review of treatment for localized prostate cancer. Prostate Disease Patient Outcome Research Team. Arch Fam Med 1993; 2: 487–93.
   Google Scholar
• Fowler FJ, Jr, Barry MJ, Lu-Yao G, Roman A, Wasson J, Wennberg JE. Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medi-care Experience: 1988-1990 (updated June 1993). Urology 1993; 42: 622–9.
   Google Scholar
• Davidson PJT, van den Ouden D, Schröder FH. Radical prostatectomy: Prospective assessment of mortality and mor-bidity. Eur Urol 1996; 29: 168–73.
   Google Scholar
• Walsh PC, Partin AW, Epstein K. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 1994; 152: 1831–6.
   Google Scholar
• Bagshaw MA, Cox RS, Ray GR. Status of radiation treat-ment of prostate cancer at Stanford University. NCI Monogr 1988; 47–60.
   Google Scholar
• Aus G, Hermansson CG, Hugosson J, Pedersen KV. Tran-srectal ultrasound examination of the prostate: Complica-tions and acceptance by patients. Br J Urol 1993; 71: 457–9.
   PubMedGoogle Scholar
• Clements R, Aideyan OU, Griffiths GJ, Peeling WB. Side effects and patient acceptability of transrectal biopsy of the prostate. Clin Radiol 1993; 47: 125–6.
   PubMed Web of Science ®Google Scholar
• Rietbergen JBW, Boeken Kruger AE, Kranse R, Schröder FH. Complications of transrectal ultrasound-guided system-atic sextant biopsies of the prostate: Evaluation of complica-tion rates and risk factors within a population-based screening program. Urology 1997; 49: 875–80.
   Google Scholar
• Nijs HGT, Todoir DM, Schuurman JH, Kirkels WJ, Schröder FH. Randomised trial of prostate cancer screening in the Netherlands: assessment of acceptance and motives for attendance. J Med Screen 1997; 4: 102–6.
   Google Scholar
• Fowler FJ, Jr, Barry MJ, Lu-Yao G, Wasson J, Roman A, Wennberg J. Effect of radical prostatectomy for prostate cancer on patient quality of life: results from a Medicare survey. Urology 1995; 45: 1007–13; discussion 1013-1015.
   Google Scholar
• Polednak AP. Trends in prostate carcinoma incidence in Connecticut (1988-1994) by age and race. Cancer 1997; 79: 99–103.
   PubMed Web of Science ®Google Scholar
• Stephenson RA, Smart CR, Mineau GR, James BC, Janer-ich DT, Dibble RL. The fall in incidence of prostate car-cinoma. Cancer 1996; 77: 1342–8.
   Google Scholar
• Hoeksema MJ, Law C. Cancer mortality rates fall: A turn-ing point for the nation. J Natl Cancer Inst 1996; 88: 1706–7.
   PubMed Web of Science ®Google Scholar
• Auvinen A, Rietbergen JBW, Denis LJ, Schröder FH, Pro-rok PC. Prospective evaluation plan for randomised trials of prostate cancer screening. The International Prostate Cancer Screening Trial Evaluation Group. J Med Screen 1996; 3: 97–104.
   Google Scholar